Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Xiaohao Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0282-1684; OpenAlex author ID A5104210116. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort … Co-author DOI 10.1002/ueg2.12688↗
  2. Retraction Note: ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experi… Co-author DOI 10.1007/s10142-024-01373-4↗
  3. ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis. Co-author DOI 10.1007/s10142-023-01122-z↗
  4. Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges. First author DOI 10.1007/s11684-023-1050-6↗
  5. Subcellular localization of nucleolar protein 14 and its proliferative function mediated by miR-17-5p and E2F4 in pancreatic cancer. Co-author DOI 10.18632/aging.204915↗
  6. Protocadherin-1 serves as a prognostic biomarker and promotes pancreatic cancer progression by suppressing CD8+ T cell infiltration through CCL5-CCR5 axis. Co-author PMID 38058826↗
  7. Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. Co-author DOI 10.1002/advs.202200818↗
  8. Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2022.887385↗
  9. Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma. Co-author DOI 10.3389/fmolb.2022.1036287↗
  10. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ijms231810316↗
  11. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. Co-author DOI 10.4240/wjgs.v13.i3.279↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongxing Du · 8 shared papers, 2021–2025 · strength 1.69
  2. Zongting Gu · 6 shared papers, 2022–2025 · strength 1.27
  3. Yunjie Duan · 5 shared papers, 2022–2025 · strength 1.11
  4. Chengfeng Wang · 4 shared papers, 2021–2024 · strength 0.89
  5. Chengfeng Wang · 3 shared papers, 2022–2023 · strength 0.61
  6. Zhichen Jiang · 2 shared papers, 2023 · strength 0.44
  7. Mingyang Liu · 2 shared papers, 2023 · strength 0.44
  8. Mingyang Liu · 1 shared paper, 2024 · strength 0.31
  9. Jianwei Zhang · 1 shared paper, 2025 · strength 0.30
  10. Chengfeng Wang · 1 shared paper, 2025 · strength 0.30
  11. Mingyang Liu · 1 shared paper, 2023 · strength 0.26
  12. Min Li · 1 shared paper, 2023 · strength 0.26
  13. Yefeng Yin · 1 shared paper, 2023 · strength 0.20
  14. Chengfeng Wang · 1 shared paper, 2022 · strength 0.20
  15. Hui‐Ju Wang · 1 shared paper, 2023 · strength 0.17
  16. Shaobo Zhang · 1 shared paper, 2023 · strength 0.17
  17. Fangxia Wang · 1 shared paper, 2023 · strength 0.17
  18. Weiwei Jin · 1 shared paper, 2023 · strength 0.17
  19. Yiping Mou · 1 shared paper, 2023 · strength 0.17
  20. Hu Ren · 1 shared paper, 2021 · strength 0.16
  21. Lipeng Zhang · 1 shared paper, 2021 · strength 0.16
  22. Hebing Chen · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.